127 related articles for article (PubMed ID: 38826376)
1. Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion.
Li P; Faraone JN; Hsu CC; Chamblee M; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Xu K; Liu SL
bioRxiv; 2024 May; ():. PubMed ID: 38826376
[TBL] [Abstract][Full Text] [Related]
2. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
[TBL] [Abstract][Full Text] [Related]
3. Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion.
Li P; Liu Y; Faraone J; Hsu CC; Chamblee M; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu SL
bioRxiv; 2024 Mar; ():. PubMed ID: 38559216
[TBL] [Abstract][Full Text] [Related]
4. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.
Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL
Cell; 2024 Feb; 187(3):585-595.e6. PubMed ID: 38194968
[TBL] [Abstract][Full Text] [Related]
5. Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants.
Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL
bioRxiv; 2023 Sep; ():. PubMed ID: 37745517
[TBL] [Abstract][Full Text] [Related]
6. Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.
Benlarbi M; Ding S; Bélanger É; Tauzin A; Poujol R; Medjahed H; El Ferri O; Bo Y; Bourassa C; Hussin J; Fafard J; Pazgier M; Levade I; Abrams C; Côté M; Finzi A
mBio; 2024 Jul; ():e0090724. PubMed ID: 38953636
[TBL] [Abstract][Full Text] [Related]
7. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
Faraone JN; Qu P; Goodarzi N; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Jones D; Gumina RJ; Liu SL
Emerg Microbes Infect; 2023 Dec; 12(2):2270069. PubMed ID: 37819267
[TBL] [Abstract][Full Text] [Related]
8. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.
Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Panchal AR; Saif LJ; Oltz EM; Zhang B; Zhou T; Xu K; Gumina RJ; Liu SL
Cell Rep; 2023 May; 42(5):112443. PubMed ID: 37104089
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD.
Liu Z; Zhou J; Wang W; Zhang G; Xing L; Zhang K; Wang Y; Xu W; Wang Q; Man Q; Wang Q; Ying T; Zhu Y; Jiang S; Lu L
Cell Rep Med; 2024 Mar; 5(3):101445. PubMed ID: 38428429
[TBL] [Abstract][Full Text] [Related]
10. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF
Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
[TBL] [Abstract][Full Text] [Related]
12. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
[TBL] [Abstract][Full Text] [Related]
13. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
[TBL] [Abstract][Full Text] [Related]
14. Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents.
Abul Y; Nugent C; Vishnepolskiy I; Wallace T; Dickerson E; Holland L; Esparza I; Winkis M; Wali KT; Chan PA; Baier RR; Recker A; Kaczynski M; Kamojjala S; Pralea A; Rice H; Osias O; Oyebanji OA; Olagunju O; Cao Y; Li CJ; Roederer A; Pfeifer WM; King CL; Bosch J; Nanda A; McNicoll L; Mujahid N; Raza S; Tyagi R; Wilson BM; White EM; Canaday DH; Gravenstein S; Balazs AB
medRxiv; 2024 Mar; ():. PubMed ID: 38585784
[TBL] [Abstract][Full Text] [Related]
15. Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster sera.
Wang W; Bhushan GL; Paz S; Stauft CB; Selvaraj P; Goguet E; Bishop-Lilly KA; Subramanian R; Vassell R; Lusvarghi S; Cong Y; Agan B; Richard SA; Epsi NJ; Fries A; Fung CK; Conte MA; Holbrook MR; Wang TT; Burgess TH; Mitre E; Pollett SD; Katzelnick LC; Weiss CD
bioRxiv; 2024 Apr; ():. PubMed ID: 38712124
[TBL] [Abstract][Full Text] [Related]
16. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
Roe TL; Brady T; Schuko N; Nguyen A; Beloor J; Guest JD; Aksyuk AA; Tuffy KM; Zhang T; Streicher K; Kelly EJ; Kijak GH
Microbiol Spectr; 2023 Mar; 11(2):e0033323. PubMed ID: 36877050
[TBL] [Abstract][Full Text] [Related]
17. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
Ao D; He X; Hong W; Wei X
MedComm (2020); 2023 Apr; 4(2):e239. PubMed ID: 36938325
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
[TBL] [Abstract][Full Text] [Related]
19. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.
Wang Q; Guo Y; Bowen A; Mellis IA; Valdez R; Gherasim C; Gordon A; Liu L; Ho DD
Cell Host Microbe; 2024 Mar; 32(3):315-321.e3. PubMed ID: 38377995
[TBL] [Abstract][Full Text] [Related]
20. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
